VirtualScopics (VSCP) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'VirtualScopics, Inc.	'	'
Entity Central Index Key	'0001307752	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'VSCP	'	'
Entity Common Stock, Shares Outstanding	'	2,991,869	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$8,018,290

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Assets	'	'
Cash	$7,330,630	$8,523,807
Accounts receivable, net of allowance for doubtful accounts of $15,000	1,725,070	1,762,507
Prepaid expenses and other current assets	397,699	437,698
Total current assets	9,453,399	10,724,012
Patents, net	1,334,420	1,470,436
Property and equipment, net	221,700	399,569
Other assets	0	5,428
Total assets	11,009,519	12,599,445
Liabilities and Stockholders' Equity	'	'
Accounts payable and accrued expenses	846,071	872,652
Accrued payroll	837,611	481,661
Unearned revenue	745,028	272,509
Dividends payable	293,333	125,333
Total current liabilities	2,722,043	1,752,155
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Common stock, $0.001 par value; 85,000,000 shares authorized; issued 2,992,853 and 2,979,952 shares at December 31, 2013 and December 31, 2012, respectively; outstanding, 2,991,869 shares at December 31, 2013 and 2,979,952 shares at December 31, 2012, respectively	2,992	2,980
Additional paid-in capital	21,992,619	21,807,904
Accumulated deficit	-13,708,141	-10,963,600
Total stockholders' equity	8,287,476	10,847,290
Total liabilities and stockholders' equity	11,009,519	12,599,445
Convertible Preferred Stock Series A [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	2	2
Convertible Preferred Stock Series B [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	1	1
Convertible Preferred Stock Series C - 1 [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	3	3
Convertible Preferred Stock Series C - 2 [Member]	'	'
Stockholders' Equity	'	'
Convertible preferred stock	$0	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Accounts Receivable	$15,000	'
Convertible preferred stock, par value (in dollars per share)	$0.00	$0.00
Convertible preferred stock, shares authorized	15,000,000	15,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	85,000,000	85,000,000
Common stock, shares Issued	2,992,853	2,979,952
Common stock, shares outstanding	2,991,869	2,979,952
Convertible Preferred Stock Series A [Member]	'	'
Convertible preferred stock, shares authorized	8,400	8,400
Convertible preferred stock, shares issued	2,190	2,190
Convertible preferred stock, shares outstanding	2,190	2,190
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series B [Member]	'	'
Convertible preferred stock, shares authorized	6,000	6,000
Convertible preferred stock, shares issued	600	600
Convertible preferred stock, shares outstanding	600	600
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series C - 1 [Member]	'	'
Convertible preferred stock, shares authorized	3,000	3,000
Convertible preferred stock, shares issued	3,000	3,000
Convertible preferred stock, shares outstanding	3,000	3,000
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000
Convertible Preferred Stock Series C - 2 [Member]	'	'
Convertible preferred stock, shares authorized	3,000	3,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Convertible preferred stock, liquidation preference (in dollars per share)	$1,000	$1,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues	$10,466,348	$11,950,447
Reimbursement revenues	707,703	1,012,717
Total revenues	11,174,051	12,963,164
Cost of services	6,047,444	6,698,992
Cost of reimbursement revenues	707,703	1,012,717
Total cost of services	6,755,147	7,711,709
Gross profit	4,418,904	5,251,455
Operating expenses	'	'
Research and development	1,510,721	1,603,177
Sales and marketing	1,556,257	1,410,877
General and administrative	3,749,130	3,079,667
Depreciation and amortization	366,527	420,733
Total operating expenses	7,182,635	6,514,454
Operating loss	-2,763,731	-1,262,999
Other income (expense)	'	'
Interest income	6,410	3,403
Other expense	-3,097	-4,469
Unrealized gain (loss) on change in fair value of the derivative liabilities	15,877	-264,587
Total other income (expense)	19,190	-265,653
Net loss	-2,744,541	-1,528,652
Preferred stock deemed dividend	0	1,806,919
Preferred stock dividends	168,000	137,333
Net loss attributable to common stockholders	($2,912,541)	($3,472,904)
Basic and diluted loss per common share (in dollars per share)	($0.98)	($1.17)
Weighted average number of common shares outstanding Basic and diluted (in shares)	2,981,732	2,964,478

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C - 1 Preferred Stock [Member]
Balances at Dec. 31, 2011	$8,477,362	$2,937	$17,909,370	($9,434,948)	$2	$1	$0
Balances (in shares) at Dec. 31, 2011	'	2,936,993	'	'	2,190	600	0
Exercise of warrants	262,500	36	262,464	'	'	'	'
Exercise of warrants (in shares)	'	35,708	'	'	'	'	'
Reclassification of derivative liabilities in connection with series C-1 preferred stock issuance	405,233	'	405,233	'	'	'	'
Exercise of employee stock options	20,200	2	20,198	'	'	'	'
Exercise of employee stock options (in shares)	'	2,000	'	'	'	'	'
Amortization of stock option expense	612,946	'	612,946	'	'	'	'
Restricted stock units issuance	68,549	5	68,544	'	'	'	'
Restricted stock units issuance (in shares)	'	5,176	'	'	'	'	'
Series B preferred stock dividends based on 8% annual rate	-48,000	'	-48,000	'	'	'	'
Series C-1 preferred stock issued in private placement, net of issuance costs of $	2,666,485	'	2,666,482	'	'	'	3
Series C-1 preferred stock issued in private placement, net of issuance costs of $ (in shares)	'	'	'	'	'	'	3,000
Series C-1 preferred stock dividends based on 4% annual rate	-89,333	'	-89,333	'	'	'	'
Net loss	-1,528,652	'	'	-1,528,652	'	'	'
Balances at Dec. 31, 2012	10,847,290	2,980	21,807,904	-10,963,600	2	1	3
Balances (in shares) at Dec. 31, 2012	'	2,979,877	'	'	2,190	600	3,000
Amortization of stock option expense	257,263	'	257,263	'	'	'	'
Amortization of restricted stock units	6,723	'	6,723	'	'	'	'
Restricted stock units issuance	88,741	12	88,729	'	'	'	'
Restricted stock units issuance (in shares)	'	11,992	'	'	'	'	'
Series B preferred stock dividends based on 8% annual rate	-48,000	'	-48,000	'	'	'	'
Series C-1 preferred stock dividends based on 4% annual rate	-120,000	'	-120,000	'	'	'	'
Net loss	-2,744,541	'	'	-2,744,541	'	'	'
Balances at Dec. 31, 2013	$8,287,476	$2,992	$21,992,619	($13,708,141)	$2	$1	$3
Balances (in shares) at Dec. 31, 2013	'	2,991,869	'	'	2,190	600	3,000

Consolidated_Statements_of_Cha1

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Series B Preferred Stock [Member]	'	'
Preferred Stock, Dividend Rate, Percentage	8.00%	8.00%
Series C - 1 Preferred Stock [Member]	'	'
Preferred Stock, Dividend Rate, Percentage	4.00%	4.00%

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities	'	'
Net loss	($2,744,541)	($1,528,652)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities	'	'
Depreciation and amortization	366,527	420,733
Loss on the disposal of long lived assets	16,761	0
Gain on the disposal of property and equipment	-2,089	0
Stock-based compensation	352,727	612,946
Fair value adjustment of derivative liabilities	-15,877	264,587
Changes in operating assets and liabilities	'	'
Accounts receivable	37,437	672,989
Prepaid expenses and other assets	45,427	-54,610
Unearned revenue	472,519	-148,977
Accounts payable and accrued expenses	-10,704	81,976
Accrued payroll	355,950	-277,809
Total adjustments	1,618,678	1,571,835
Net cash (used in) provided by operating activities	-1,125,863	43,183
Cash flows from investing activities	'	'
Purchases of property and equipment	-78,207	-170,413
Proceeds from the sale of equipment	28,441	0
Patent applications and maintenance	-17,548	-23,157
Net cash used in investing activities	-67,314	-193,570
Cash flows from financing activities	'	'
Proceeds from the exercise of stock options	0	20,200
Proceeds from the exercise of warrants	0	262,500
Proceeds from the issuance of series C-1 preferred stock and warrant, net of issuance costs	0	2,666,485
Cash dividends on series B preferred stock	0	-12,000
Net cash provided by financing activities	0	2,937,185
Net (decrease) increase in cash	-1,193,177	2,786,798
Cash	'	'
Beginning of year	8,523,807	5,737,009
End of year	7,330,630	8,523,807
Non-cash financing activities:	'	'
Issuance of restricted awards in settlement of accrued liability for board fees	0	68,549
Accrued dividends on series B and C-1 preferred stock	168,000	125,333
Reclassification of derivative liabilities to additional paid in capital in connection with the series C-1 preferred stock issuance	$0	$405,233

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Organization and Basis Of Presentation [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	NOTE 1 - Organization and Basis of Presentation
	Nature of Business
	The Company’s headquarters are located in Rochester, New York. The Company has created a suite of image analysis software tools and applications which are used in detecting and analyzing specific structures in medical images. The Company’s developed software provides measurement and visualization capabilities designed to improve clinical research and development.
	Basis of Presentation
	A Certificate of Amendment to effect a reverse stock split was approved by the Company's stockholders at its Annual Meeting of Stockholders held on August 13, 2013.  The Company's stockholders granted the Board authority to effectuate a reverse stock split at a ratio of between 1-for-2 to 1-for-10. The Company’s Board of Directors subsequently approved a 1-for-10 reverse stock split of the Company’s outstanding common stock that was effected on August 21, 2013. Corresponding adjustments were made to the number of shares of common stock underlying the Company’s outstanding options, warrants, and preferred stock exercisable for or convertible into common stock and the related long-term incentive plans for such options. All share and related option information presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the reduced number of shares resulting from this action.
	On August 29, 2012, the Company received written notice from the Nasdaq Stock Market (“Nasdaq”) that the Company was out of compliance with Rule 5550(a)(2) of the Nasdaq Marketplace rules, the minimum bid price requirements. Thereafter, Nasdaq granted the Company an extension until August 26, 2013 to regain compliance. On September 5, 2013, the closing price of the Company's common stock was $4.84 per share which marked the tenth consecutive day the stock price had a closing bid price above $1.00 per share resulting in the Company regaining compliance with Nasdaq.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 2 - Summary of Significant Accounting Policies
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of VirtualScopics, Inc. and its wholly-owned subsidiary, VirtualScopics, LLC. All significant intercompany balances and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates. Estimates included in these consolidated financial statements relate to assessing the collectability of accounts receivable, the valuation of securities underlying share-based compensation and derivative financial instruments, realization of deferred tax assets, tax contingencies and any related valuation allowance, and the useful lives and potential impairment of the Company’s property and equipment and intangible assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that they are determined to be necessary.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments when purchased with a maturity of three months or less to be cash equivalents. At December 31, 2013 and 2012, the Company had no cash equivalents.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash. At times, our cash may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits.
	Accounts Receivable
	Accounts receivable are stated at estimated net realizable value.  Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts, if any. In determining collectability, historical trends are evaluated and specific customer issues are reviewed to arrive at appropriate allowances, if any.
	Patents
	Costs incurred to acquire and file for patents, including legal costs, are capitalized as long-lived assets and amortized on a straight-line basis over the lower of the estimated useful life or legal life of the patent, which is 20 years.
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation. When retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any resulting gain or loss is recognized and included in the consolidated statement of operations.
	Expenditures for maintenance and repairs, which do not generally extend the useful life of the assets, are charged to expense as incurred. Gains or losses on disposal of property and equipment are reflected in other expense in the consolidated statement of operations in the period of disposal.
	Depreciation is computed using the straight-line method over the following useful lives:
		Years
	Office/computer equipment	5-Mar
	Furniture and fixtures	7-May
	Software	3
	Leasehold improvements, which are included in property and equipment, are recorded at cost less accumulated depreciation. Depreciation on leasehold improvements is computed using the straight-line method over the shorter of their estimated useful lives or the lease term, whichever is shorter.
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets, including intangible assets other than goodwill, for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. In connection with this review, the Company also re-evaluates the periods of depreciation and amortization for these assets. The Company assesses recoverability by determining whether the net book value of the related asset will be recovered through the projected undiscounted future cash flows of the asset. If the Company determines that the carrying value of the asset may not be recoverable, it measures any impairment based on the projected future discounted cash flows as compared to the asset’s carrying value. Through December 31, 2013, the Company has not recorded any impairment charges on its long-lived assets.
	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses the Black-Scholes option valuation model to value the derivative instruments at inception and on subsequent valuation dates. The warrants issued with the Company’s series B preferred stock, and to the placement agent in the series B financing, do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future. The Company was required to include the reset provisions in order to protect the warrant holders from the potential dilution associated with future financings. Accordingly, the warrants are recognized as a derivative instrument. The Company determined the warrants include an implied downside protection feature and performed a Monte-Carlo simulation and concluded that the value of the feature is de minimus and the use of the Black-Scholes valuation model is considered to be a reasonable method to value the warrants. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date (Note 5).
	Revenue Recognition
	The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services are performed, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any.
	The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data, and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged as an hourly rate.
	Occasionally, the Company provides software development services to its customers, which may require significant development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software in its ordinary course of business, software licenses, upgrades or enhancements, or post-contract customer services.
	Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as reimbursement revenues and cost of reimbursement revenues, respectively, in the consolidated financial statements.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
	Research and Development
	Research and development expense relates to the development of new applications and processes, including improvements to existing applications. These costs are expensed as incurred.
	Fair Value of Financial Instruments
	Fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy. See Note 5 – Derivative Liabilities for a further discussion regarding the Company’s measurement of financial assets and liabilities at fair value.
	Preferred Stock
	The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
	Convertible Instruments
	The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.
	Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.
	The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with Accounting Standards Codification (“ASC”) 470-20 “Debt with Conversion and Other Options”. The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.
	Common Stock Purchase Warrants and Other Derivative Financial Instruments
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock as defined in ASC 815-40 "Contracts in Entity's Own Equity" (“ASC 815-40”). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).  The Company assesses classification of common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.
	Recently Issued and Adopted Accounting Pronouncements
	The Financial Accounting Standards Board, the Emerging Issues Task Force and the SEC have issued certain accounting standards, updates and regulations as of December 31, 2013 that will become effective in subsequent periods; however, management of the Company does not believe that any of those standards, updates or regulations would have significantly affected the Company’s financial accounting measures or disclosures had they been in effect during 2013 or 2012, and it does not believe that any of them will have a significant impact on the Company’s consolidated financial statements at the time they become effective.
	Stock-Based Compensation
	The Company accounts for share-based awards exchanged for employee services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a three or four year period.
	The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, and expected dividend yield. The risk free interest rate is based on U.S. Treasury zero-coupon yield curve over the expected term of the option. The expected term assumption is determined using the weighted average midpoint between vest and expiration for all individuals within the grant. Through the second quarter of 2012, the Company had estimated its expected volatility from an index of historical stock prices of comparable entities whose share prices were publicly traded and averaged with the Company’s historical stock prices, excluding its first ten months of activity due to the discreet and non-recurring nature of the trading. Beginning in the third quarter of 2012, the Company began estimating its expected volatility using only its own historical stock prices, continuing to exclude the first ten months due to the discreet and non-recurring nature of the trading, as management determined this assumption to be a better indicator of value at this time. The Company’s model includes a zero dividend yield assumption, as the Company has not historically paid nor does it anticipate paying dividends on its common stock. The Company’s model does not include a discount for post-vesting restrictions, as the Company has not issued awards with such restrictions. The periodic expense is then determined based on the valuation of the options, and at that time an estimated forfeiture rate is used to reduce the expense recorded. The Company’s estimate of pre-vesting forfeitures is primarily based on the Company’s historical experience and is adjusted to reflect actual forfeitures as the options vest. The estimated forfeiture rates used during the years ended December 31, 2013 and 2012 ranged from 7.1% to 7.3%.
	The following assumptions were used to estimate the fair value of options granted for the years ended December 31, 2013 and 2012 using the Black-Scholes option-pricing model:
		December 31,
		2013			2012
	Risk free interest rate		1.97	%		1.13	%
	Expected term (in years)		6.7			6.32
	Expected volatility		68.22	%		57.98	%
	Expected dividend yield		-			-
	Loss Per Share
	Basic loss per share are computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method) and the conversion of the Company’s convertible preferred stock and warrants (using the if-converted method). Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, the exercise of stock options and warrants from the calculation of net loss per share as their effect would be antidilutive.
	Securities that could potentially dilute earnings per share in the future that were not included in the computation of diluted loss per share consist of the following numbers of shares into which preferred stock could have been converted and shares for which outstanding options and warrants could have been exercised during the years ending December 31, 2013 and 2012:
		2013		2012
	Convertible preferred stock	480,777		480,777
	Warrants to purchase common stock	233,753		238,302
Non-vested restricted stock awards	984		-
Options to purchase common stock	425,995		598,044
Total	1,141,509		1,317,123

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 3 - Property and Equipment
	Property and equipment consisted of the following as of December 31:
		2013		2012
	Office/computer equipment	$	876,393	$	917,638
	Furniture and fixtures		267,939		267,939
	Software		468,226		446,611
	Leasehold improvements		114,669		143,109
			1,727,227		1,775,297
	Less: accumulated depreciation		-1,505,527		-1,375,728
		$	221,700	$	399,569
	Depreciation expense amounted to $229,724 and $285,074 for the years ended December 31, 2013 and 2012, respectively. The Company disposed of and wrote-off property and equipment with an original cost of $126,277 and accumulated depreciation of $99,925 during the year ended December 31, 2013, which resulted in a net gain of $2,089 and cash proceeds of $28,441. During the year ended December 31, 2012, the Company disposed of and wrote-off property and equipment with $86,297 of cost and $86,297 of accumulated depreciation.

Patents

Patents	12 Months Ended
	Dec. 31, 2013
Patents [Abstract]	'
Patents [Text Block]	'
	NOTE 4 - Patents
	On May 24, 2002, the Company purchased from the University of Rochester, a related party, certain patents developed by the Company’s founders and previously licensed by the Company under an Exclusive Right Agreement. The Company paid $1,500,000 and issued warrants to acquire 357,075 shares of common stock to the University of Rochester for the full right and title to the patents. The warrants were recorded at fair value which totaled $157,000. Since May 24, 2002, the Company has invested an additional $1,075,990 in connection with improving and expanding its patent portfolio. These costs consist predominately of legal and filing fees and historically been capitalized as long-lived assets. For the years ended December 31, 2013 and 2012, the Company capitalized $17,548 and $23,157, respectively, of legal expenses and filing fees associated with the maintenance of its patents. During 2013, the Company wrote off $16,761 in legal expenses associated with pending patent applications.
	Accumulated amortization on the patents amounted to $1,379,213 and $1,242,410 as of December 31, 2013 and 2012, respectively. Amortization expense for the years ended December 31, 2013 and 2012 amounted to $136,803 and $135,659, respectively. The weighted-average remaining amortization period is approximately 13 years as of December 31, 2013. The estimated future amortization of the patents is as follows:
	For the Years Ending
	December 31,	Amount
	2014	$	137,574
	2015		137,574
	2016		137,574
	2017		137,574
	2018		137,574
	Thereafter		646,550
	Total	$	1,334,420

Derivative_Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	NOTE 5 - Derivative Liabilities
	The warrants issued with the Company’s Series B Convertible Preferred stock, and to the placement agent in the Series B financing, do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future. The Company was required to include the reset provisions in order to protect the warrant holders from the potential dilution associated with future financings.
	The derivative liabilities were valued using the Black-Scholes option valuation model and the following assumptions on the following dates:
		April 3, 2012				December 31, 2012				December 31, 2013
	Series B warrants:
	Risk-free interest rate		0.45	%			0.22	%			0.13	%
	Expected volatility		49.6	%			65.94	%			56.31	%
	Expected life (in years)		2.43				1.69				0.69
	Expected dividend yield		-				-				-
	Number of warrants		90,204				21,423				21,423
	Fair value	$	521,139			$	15,950			$	73
	The risk-free interest rate was based on rates established by the Federal Reserve. The Company’s policy for expected volatility is disclosed in Note 2. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based upon the fact that the Company has not historically paid dividends on its common stock, and does not expect to pay dividends on its common stock in the future.
	As part of the Company’s Series C-1 Preferred Stock and Warrant financing (as disclosed in Note 6), the Company agreed with certain holders of the majority of the outstanding Series B Warrants to amend and restate the terms of those warrants. As a result of the amended and restated terms, the anti-dilution adjustment provision, which required the Company to reduce the exercise price of the Series B Warrants if the Company had issued shares at a lower price, contained in the agreements was eliminated on 76,198 warrants. As of December 31, 2013, the Company had 21,423 warrants outstanding subject to the anti-dilution adjustment provision.
	The fair value of these warrant liabilities was $73 and $15,950 at December 31, 2013 and 2012, respectively. The net change in fair value during 2013 is $15,877, of which is reported in the Company’s consolidated statement of operations as an unrealized gain on the change in fair value of the derivative liabilities. The net change in fair value during 2012 was $140,646, of which $264,587 was reported in the Company’s consolidated statement of operations as an unrealized loss on the change in fair value of the derivative liabilities and $405,233 was a reclassification of the fair value of the derivative liabilities to equity in connection with the Series C-1 financing disclosed above. The fair value of the derivative liabilities are re-measured at the end of every reporting period, when certain terms to the warrant agreements are amended, and/or upon the exercise of the warrant. The change in fair value is reported in the consolidated statement of operations as an unrealized gain or loss on the change in fair value of the derivative liability and in the consolidated balance sheets as accounts payable and accrued expenses.
	Fair Value Measurement
	Valuation Hierarchy
	ASC 820, “Fair Value Measurements and Disclosures,” establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.
	The following table provides the liabilities carried at fair value measured on a recurring basis as of December 31, 2013 and 2012:
					Fair Value Measurements at December 31, 2013
		Total			Quoted			Significant			Significant
		Carrying			prices in			other			unobservable
		Value at			active			observable			inputs
		December 31,			markets			inputs			(Level 3)
		2013			(Level 1)			(Level 2)
	Derivative liabilities	$	73		$	-		$	-		$	73
					Fair Value Measurements at December 31, 2012
		Total			Quoted			Significant			Significant
		Carrying			prices in			other			unobservable
		Value at			active			observable			inputs
		December 31,			markets			inputs			(Level 3)
		2012			(Level 1)			(Level 2)
	Derivative liabilities	$	15,950		$	-		$	-		$	15,950
	The carrying amounts of cash, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities approximate their fair value due to their short maturities. The Company measures the fair value of financial assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value.
	Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivative liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s Chief Financial Officer, determines its valuation policies and procedures.  The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s Chief Financial Officer.
	Level 3 Valuation Techniques
	Level 3 financial liabilities consist of the derivative liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation.  Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.
	The Company uses the Black-Scholes option valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates.  This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as, volatility.
	A significant decrease in the volatility or a significant decrease in the Company’s stock price, in isolation, would result in a significantly lower fair value measurement. Changes in the values of the derivative liabilities are recorded in Change in Fair Value of Derivative Liabilities within Other Income (Expense) on the Company’s Consolidated Statements of Operations.
	As of December 31, 2013, there were no transfers in or out of level 3 from other levels in the fair value hierarchy.
	The following table sets forth a summary of the changes in the fair value of our Level 3 financial liabilities that are measured at fair value on a recurring basis:
		Years Ended December 31,
		2013			2012
	Beginning balance	$	15,950		$	156,596
	Net unrealized (gain) loss on derivative financial instruments		-15,877			264,587
	Reclassification to stockholders’ equity					-405,233
	Ending balance	$	73		$	15,950

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 6 – Stockholders’ Equity
	Common Stock
	The Company has authorized 85,000,000 shares of common stock, par value $0.001. As of December 31, 2013, the Company had reserved 232,794 shares of common stock for issuance under its 2001 and 2005 long-term incentive plans, another 35,000 shares of common stock issued to a previous CEO outside of one of its long-term incentive plans, and 690,000 shares for its 2006 Long-term Incentive Plan.
	Preferred Stock
	The Company has authorized 15,000,000 shares of preferred stock, par value $0.001 per share, of which 8,400 are designated as Series A Convertible Preferred Stock (“Series A”), 6,000 are designated as Series B Convertible Preferred Stock (“Series B”), 3,000 are designated as Series C-1 Convertible Preferred Stock (“Series C-1”), and 3,000 are designated as Series C-2 Convertible Preferred Stock (“Series C-2”) as specified in the Certificate of Designation (the “Certificate”). During the year ended December 31, 2013 and 2012, there were no conversions of the Company’s convertible preferred stock.
	Each share of Series A is convertible into 83.036 shares of the Company’s common stock and is senior in liquidation preference in comparison to shares of the Company’s common stock.
	Each share of Series B is convertible into 83.036 shares of the Company’s common stock and has a liquidation preference that is pari passu with the Company’s Series A and senior to the Company’s common stock. Cumulative dividends on the Series B accrue on the stated value of $1,000 per share at an annual rate of 8%, payable monthly in cash and/or shares of the Company’s common stock at the option of the Company. As of December 31, 2013, there were $84,000 of dividends payable to Series B stockholders. During the years ended December 31, 2013 and 2012, cash dividends paid aggregated to $0 and $12,000, respectively. As of December 31, 2013, 21,423 warrants that were issued with the Company’s Series B remain issued and outstanding.
	On April 3, 2012, the Company and Merck Global Health Innovation Fund, LLC (“GHI”) entered into a Series C Preferred Stock and Warrant Purchase Agreement (the “Purchase Agreement”) under which the Company agreed to sell GHI up to 6,000 shares of the Company’s Series C Preferred Stock and warrants to purchase up to 272,263 shares of common stock at an exercise price of $12.043 per share (the “Series C Warrants”) for a purchase price of $6,000,000 in two separate closings. The Series C Preferred Stock is convertible, at GHI’s election, into shares of the Company’s common stock at a conversion rate, which is determined by dividing (i) the stated value per share of $1,000, plus, if consented to by the Company, all accrued and unpaid dividends, by (ii) the conversion price of $12.043. The conversion price of the Series C Preferred Stock and exercise price of the Series C Warrants is subject to customary anti-dilution provisions.
	The initial closing under the Purchase Agreement took place on April 3, 2012 at which the Company sold to GHI 3,000 shares of Series C-1 Preferred Stock which are initially convertible into 249,107 shares of common stock and Series C-1 Warrants which are exercisable to purchase 136,132 shares of common stock for a purchase price of $3,000,000, net of issuance costs of approximately $334,000. The warrants contain a seven year term and became exercisable on September 30, 2012. The terms of the financing provided for a second closing of $3,000,000 of Series C-2 Preferred Stock, if, among other things, certain milestones are met toward the development of its quantitative imaging center on or before April 3, 2013. The second closing did not occur.
	The Series C-1 Preferred Stock has a 4% cumulative dividend and is senior in liquidation preference to the existing preferred stock and common stock. The Series C-1 holders elected to accrue the dividends making the dividends payable on the earlier of the liquidation of the corporation according to the Series C Certificate of Designation or upon the conversion of the Series C-1 into common stock. Subject to certain exceptions, the Series B holders are only entitled to be paid dividends, if full dividends are first paid or concurrently paid to the holders of the Series C-1 Preferred Stock. As of December 31, 2013, dividends payable to Series C-1 convertible preferred stockholders amounted to $209,333 and are included in dividends payable on the Company’s consolidated balance sheet.
	In accordance with ASC 470, “Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios,” the Series C-1 convertible preferred stock was considered to have an embedded beneficial conversion feature as the effective conversion price was less than the fair value of the Company’s common stock at the issuance date. This beneficial conversion feature is calculated after the warrants have been valued with proceeds allocated on a relative fair value basis. The value of the beneficial conversion feature was calculated using, among other factors, the Company’s closing stock price of $15.60 on April 3, 2012 resulting in the recognition of a one-time non-cash deemed dividend of $1,806,919 during the year ended December 31, 2012.

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	NOTE 7 – Share-Based Compensation
	Stock Options
	As of December 31, 2013, the Company’s 2001 Long-Term Incentive Plan, 2005 Long-Term Incentive Plan and 2006 Long-Term Incentive Plan had a total of 425,995 in stock option grants. In May 2007, the stockholders of the Company approved the adoption of the Company’s 2006 Stock Plan (the “Plan”). The Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to employees and for the grant of non-statutory stock options, restricted stock, and stock appreciation rights to employees, directors, and consultants. The Compensation Committee of the Company’s board of directors administers the Plan and has the authority to make awards under the Plan and establish vesting and other terms, but cannot grant stock options at less than the fair value of the Company’s common stock on the date of grant or re-price stock options previously granted. The employee stock options granted under the Plan generally vest ratably over three to four years of service and expire seven to ten years from the date of grant (or ninety days after the termination of employment). As of December 31, 2013, 251,155 stock options remained eligible for grant under the 2006 Long-Term Incentive Plan. The 2001 and 2005 Long-Term Incentive Plans have been closed for additional grants.
	During the years ended December 31, 2013 and 2012, the Company granted options to employees to purchase 6,850 and 40,580 shares of common stock, respectively. These options generally vest ratably during the first four years following their issuance and have a ten-year life. No options were exercised in 2013 and there were 2,000 options exercised resulting in cash proceeds of $20,200 during 2012. Additionally, there were 124,731 shares forfeited by the CEO and CFO during 2013.
	A summary of the employee stock option activity for the years ended December 31, 2013 and 2012 are as follows:
		Number of			Weighted		Weighted-			Aggregate
		Shares			Average		Average			Intrinsic
					Exercise		Remaining			Value
					Price		Contractual
							Term
	Options outstanding at January 1, 2012		576,869		$	13.25		6.32		$	55,000
	Granted		40,580			11.3
	Exercised		-2,000			-10.1
	Forfeited		-10,282			-14.98
	Expired		-7,663			-19
	Options outstanding at December 31, 2012		597,504			13.03		5.62		$	6,750
	Granted		6,850			5.65
	Exercised		-
	Forfeited		-143,568			-12.35
	Expired		-34,911			-18.11
	Options outstanding at December 31, 2013		425,875			12.72		4.34		$	-
	Options exercisable at December 31, 2013		372,989			12.76		4.74		$	-
	Additional information with respect to the outstanding employee stock options as of December 31, 2013 is as follows:
		Options Outstanding					Options Exercisable
	Exercise Prices	Number		Weighted		Weighted	Number		Weighted
		Outstanding at		Average		Average	Exercisable		Average
		December 31,		Remaining		Exercise	at		Exercise
		2013		Life		Price	December		Price
				(Years)			31, 2013
	$ 4.80 – 9.20	69,663		5.67		7.95	59,926		8.19
	$ 9.21 – 10.15	126,100		4.63		9.83	126,000		9.83
	$ 10.16 – 12.05	108,745		4.21		11.56	94,952		11.61
	$ 12.06 – 21.75	70,459		7.01		15.07	41,203		15.07
	$ 21.76 – 41.50	50,908		1.95		25.65	50,908		25.65
		425,875		4.77		12.72	372,989		12.76
	The weighted-average grant-date fair value of options granted during the years ended December 31, 2013 and 2012 was $25,081 and $250,571, respectively.
	For the years ended December 31, 2013 and 2012, the Company’s consolidated statements of operations reflect $257,263 and $612,946, respectively, of stock-based compensation expense for stock options granted under its long-term incentive plans, which is allocated as follows:
		For Years Ended December 31,
		2013			2012
	Cost of service revenues	$	50,466		$	57,984
	Research and development		64,917			78,456
	Sales and marketing		11,101			10,222
	General and administrative		130,779			466,284
	Total stock-based compensation	$	257,263		$	612,946
	A summary of the status of the non-vested shares as of December 31, 2013 and changes during the years ended December 31, 2013 and 2012, is presented below:
	Non-vested Shares	Shares		Weighted-
				Average
				Grant-Date
				Fair Value
				Per Share
	Non-vested at January 1, 2012	234,647		$	12.47
	Granted	40,580			11.3
	Vested.	-94,484			-11.38
	Cancelled Grants	-7,807			-14.72
	Non-vested at December 31, 2012	172,936		$	12.69
	Granted	6,850			5.65
	Vested	-78,722			-11.88
	Cancelled Grants	-48,178			-13.26
	Non-vested at December 31, 2013	52,886		$	12.46
	As of December 31, 2013, there was $205,194 of total unrecognized compensation cost related to non-vested share-based compensation arrangements. This cost is expected to be recognized over a weighted-average period of 1.80 years. The total fair value of shares vested during the year ended December 31, 2013 amounted to $569,988.
	Prior to 2008, the Company issued options under the 2006 Long-Term Incentive Plan to non-employee consultants for radiological services performed. These options to non-employees generally vested immediately, had exercise prices ranging from $1.12 to $6.85 and a term of seven or six years from the date of grant. The value of the options was based on the fair value of the services performed and were included in the Company’s statements of operations. During 2013, a total of 421 of the non-employee options expired.
	The total amount of stock options outstanding as of December 31, 2013 is:
	Stock options granted to employees	425,875
Stock options granted to consultants	120
Total outstanding	425,995
During 2013, a total of 6,850 stock options were granted, of that amount 1,000 were granted to executive officers of the Company.
Restricted Stock Awards
A restricted stock award entitles the recipient to receive shares of unrestricted common stock upon vesting of the award and expiration of the restrictions. The fair value of each restricted stock award is determined upon granting of the shares and the related compensation expense is recognized ratably over the vesting period and charged to the operations as non-cash compensation expense. Shares contained in the unvested portion of restricted stock awards are forfeited upon termination of employment, unless otherwise agreed. The fair value of restricted stock issued under the Plan is determined based on the closing price of the Company’s common stock on the grant date. Under the provisions of the 2006 Long Term Incentive Plan, the Company may grant restricted stock to its employees, board members and consultants. During 2006, the Board of Directors Compensation Committee approved an equity based compensation structure for non-employee Board members.
A summary of the restricted stock award activity for the year ended December 31, 2013 is as follows:
	Number		Weighted
	of Units		Average
			Grant
			Date Fair
			Value
Non-vested at January 1, 2013	-
Granted	15,927		7.4
Vested	-11,992		-7.4
Cancelled/Forfeited	-2,951		-7.4
Non-vested at December 31, 2013	984		7.4
The Company incurred $95,464 and $0 in compensation expense during the year ended December 31, 2013 and 2012, respectively, related to the restricted stock awards granted to Board members and former officers of the Company. During 2013, the Company issued an aggregate 15,927 stock awards to the former CEO and CFO, which had a grant date fair value of $117,861 ($7.40 per share) and vest over a four year period. On August 31, 2013, 2,951 restricted stock awards were forfeited as the result of the resignation of the former CFO. On October 25, 2013, as part of the separation agreement with the former CEO, the vesting was accelerated for 11,992 shares underlying restricted stock units to the date of termination.
In 2012, 51,761 in stock awards were issued to members of the Board for their services on the Board under the 2006 Long Term Incentive Plan. The stock awards are fully vested and non-forfeitable and are therefore included in the outstanding common stock of the Company as of December 31, 2013. The weighted average grant date fair value of stock issued by the Company during 2012 was $68,549. No stock awards were issued to the members of the Board in 2013.

Benefit_Plan

Benefit Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	NOTE 8 - Benefit Plan
	The Company has a defined contribution plan which covers all of its full-time employees. The employees’ annual contributions are limited to the maximum allowed under the Internal Revenue Code. During 2009, the Company began a matching contribution to participants 401k plans equal to 50% of the participants’ contributions up to a maximum 3% of annual wages. In 2013, the Company discontinued matching the contributions of 401K plan participants. The Company paid a total of $0 and $145,479 in 2013 and 2012 to participants representing the employer contribution amount.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 9 - Income Taxes
	The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions, as defined. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s consolidated financial statements. The Company’s evaluation was performed for the tax years ended 2010 through 2013, the only periods subject to examination. The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. The Company does not expect its unrecognized tax benefit to change during the next 12 months. As of December 31, 2013, all of the Company’s deferred tax assets were fully reserved by a valuation allowance equal to 100% of the net deferred tax assets. During 2014, the Company will assess the likelihood of recognizing a portion of its deferred tax assets and will make an assessment of whether it should reduce the valuation allowance.
	The Company has significant net operating loss and business credit carryovers which are subject to a valuation allowance due to the uncertain nature of the realization of the losses. Section 382 of the Internal Revenue Code imposes certain limitations on the utilization of net operating loss carryovers and other tax attributes after a change in control.  If the Company has a change in ownership, such change could significantly limit the possible utilization of such carryovers.
	The Company will recognize interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. The Company does not have any interest and penalties accrued related to unrecognized tax benefits.
	The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Under ASC 740, deferred income taxes and liabilities are recognized based on temporary differences between the financial statement and tax basis of assets and liabilities using the enacted tax rates in effect in the years in which the differences are expected to reverse. ASC 740 requires recognition of net deferred tax assets to the extent it is more likely than not that such net assets will be realized. To the extent that the Company believes that its net deferred tax assets will not be realized, a valuation allowance must be recorded against those assets.
	The income tax provision (benefit) consists of the following:
		2013		2012
	Current
	Federal	$	-	$	-
	State		-		-
			-		-
	Deferred
	Federal		-846,095		-309,448
	State		-99,926		-42,649
	Change in valuation allowance		946,021		352,097
			-		-
	Total income tax provision	$	-	$	-
	The Company has net operating loss carryforwards (“NOLs”) of approximately $11,264,000 as of December 31, 2013 that will be available to offset future taxable income.  Approximately $677,000 of the NOL carryforwards, if realized, will result in a benefit to be recorded in APIC. The NOLs are due to expire in 2026 through 2033.  The Company has concluded that a full valuation allowance was appropriate for the NOLs as they are more likely not to be utilized prior to their expiration.
	The total net deferred tax asset and liabilities as of December 31, 2013 and 2012 consists of the following:
		2013		2012
	Net operating loss carryforwards	$	4,095,519	$	3,112,584
	Intangible assets		658,055		788,990
	Accrued expenses		146,249		117,010
	Credit carryforwards		287,756		166,693
	Stock-based compensation		958,607		1,095,050
	Total deferred tax asset		6,146,186		5,280,327
	Deferred tax liability:
	Property and equipment		-11,526		-91,688
	Subtotal		6,134,660		5,188,639
	Less: valuation allowance		6,134,660		5,188,639
	Total net deferred tax asset	$	-	$	-
	The difference between the U.S. federal statutory and effective income tax rates for the years ended December 31, 2013 and 2012 is as follows:
		2013		2012
	U.S. federal statutory tax rate	-34	%	-34	%
	State and local income taxes, net of federal benefit	-3.64		-2.67
	Stock-based compensation	7.56		8.27
	(Gain) loss from derivative financial instrument	-0.2		5.88
	Research and development credit	-4.41		-0.97
	Other	-0.17		0.46
		-34.86		-23.03
	Less: valuation allowance	34.86		23.03
	Provision for income taxes	-	%	-	%

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 10 - Commitments and Contingencies
	Operating Leases
	In July, 2007 the Company began leasing approximately 19,500 square feet of office space at our corporate headquarters in Rochester, New York. In June 2012, the Company renewed its lease for approximately 19,500 square feet of office space at the corporate headquarters in Rochester, New York. The lease term is for five years and commenced on July 1, 2012. The base annual rent under the lease is $309,075, and increases two percent (2%) per year over the term of the lease.
	In April 2010, the Company entered into a lease agreement for certain equipment. The lease was for 36 months and expired in March 2013. The base annual rent under the lease was $5,222, with $1,306 being recognized in 2013.
	Total rent expense for the years ended December 31, 2013 and 2012 was $322,993 and $326,215, respectively.
	Future minimum rental commitments under non-cancelable operating leases are as follows:
	For the Years Ending
	December 31,	Amount
	2014		318,409
	2015		324,777
	2016		331,273
	2017		167,276
	Total	$	1,141,735
	On October 25, 2013, the Company entered into a Separation, Waiver and Release Agreement (the “Separation Agreement”) with its former Chief Executive Officer, L. Jeffrey Markin. Under the terms of the Separation Agreement, Mr. Markin will receive monthly separation payments in the amount of $25,310 commencing on the date of the Separation Agreement and continuing until May 31, 2014, In addition, Mr. Markin will receive $8,213 in benefits through May 31, 2014, on terms comparable to the benefits provided for under his existing Employment Agreement with the Company dated February 24, 2009, as amended by the Amendment to Employment Agreement, dated December 28, 2012 (as amended, the “Employment Agreement”). The Employment Agreement was terminated and superseded by the Separation Agreement. Mr. Markin will also receive a $98,136 bonus earned under the Company’s 2013 Bonus Plan. Unvested stock options, stock awards and restricted stock units granted to Mr. Markin will be forfeited as of the effective date of the Separation Agreement, other than 11,992 shares underlying restricted stock units for which vesting was accelerated to the date of termination. As of December 31, 2013, there was a $20,867 receivable for the employee payroll taxes resulting from the issuance of the 11,992 shares to Mr. Markin which was reported as part of prepaid expenses and other current assets in the Company’s consolidated balance sheet. Also under the Separation Agreement, Mr. Markin provided a general release in favor of the Company and its affiliates. Mr. Markin is also obligated to comply with existing covenants not to compete, for nine months following the separation date, and of confidentiality. As of December 31, 2013, there remained approximately $133,897 of severance payable which was reported as part of accrued payroll in the Company’s consolidated balance sheet.
	In connection with the resignation of the former CEO, the Company entered into a Services Agreement with Converse & Company, dated October 25, 2013 (the “Services Agreement”), pursuant to which Eric T. Converse, a principal and shareholder of Converse & Company, will serve as interim President and Chief Executive Officer of the Company. Mr. Converse is also a director of the Company. Mr. Converse will perform the duties and responsibilities as are customary for the President and Chief Executive Officer of a company and report to, and be subject to the supervision of, the Board of Directors of the Company.  Converse & Company’s fees are based upon a monthly rate of $25,310, for an initial term of 6 months, which may be extended by the Company on a month-to-month basis.   The Services Agreement may be terminated by either the Company or Converse & Company on notice to the other, provided that a minimum 6 month payment is due unless terminated for cause by the Company or terminated by Converse & Company other than for good reason, each as defined in the Services Agreement.

Related_Parties

Related Parties	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 11 - Related Parties
	In April 2012, the Company issued Merck Global Health Innovation Fund, LLC (a wholly-owned subsidiary of Merck & Co, Inc. (“Merck”)) 3,000 shares of Series C-1 Preferred Stock which are initially convertible into 249,107 shares of common stock and Series C-1 Warrants which are exercisable to purchase 136,132 shares of common stock (See Note 6). Revenues generated from Merck were $368,977 and $1,127,330 for the years ended December 31, 2013 and 2012, respectively. The accounts receivable balance due from Merck was $87,200 and $96,096 as of December 31, 2013 and 2012, respectively.

Concentration_of_Credit_Risk

Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Concentration Risk Disclosure [Text Block]	'
	NOTE 12 – Concentrations of Credit Risk
	The Company’s top three customers accounted for approximately 42%, 12%, and 11% of total revenue for the year ended December 31, 2013. One customer accounted for 45% of total revenue for the year ended December 31, 2012.
	Four customers accounted for approximately 34%, 13%, 13%, and 11% of accounts receivable as of December 31, 2013 as compared to two customers accounting for 45% and 10% of accounts receivable as of December 31, 2012.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 13 – Subsequent Events
	On March 23, 2014, VirtualScopics, Inc. entered into a Services Extension Agreement with Converse & Company (the “Extension Agreement”). The Extension Agreement extends the term of the Services Agreement (as disclosed in Note 10), which would otherwise have expired on April 18, 2014, for an additional three months. Under the Extension Agreement, the term of the Services Agreement shall therefore expire on July 18, 2014, unless further extended pursuant to the terms and conditions of the Services Agreement.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of VirtualScopics, Inc. and its wholly-owned subsidiary, VirtualScopics, LLC. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates. Estimates included in these consolidated financial statements relate to assessing the collectability of accounts receivable, the valuation of securities underlying share-based compensation and derivative financial instruments, realization of deferred tax assets, tax contingencies and any related valuation allowance, and the useful lives and potential impairment of the Company’s property and equipment and intangible assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the period that they are determined to be necessary.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments when purchased with a maturity of three months or less to be cash equivalents. At December 31, 2013 and 2012, the Company had no cash equivalents.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash. At times, our cash may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limits.
Accounts Receivable [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable are stated at estimated net realizable value.  Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts, if any. In determining collectability, historical trends are evaluated and specific customer issues are reviewed to arrive at appropriate allowances, if any.
Patents [Policy Text Block]	'
	Patents
	Costs incurred to acquire and file for patents, including legal costs, are capitalized as long-lived assets and amortized on a straight-line basis over the lower of the estimated useful life or legal life of the patent, which is 20 years.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation. When retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any resulting gain or loss is recognized and included in the consolidated statement of operations.
	Expenditures for maintenance and repairs, which do not generally extend the useful life of the assets, are charged to expense as incurred. Gains or losses on disposal of property and equipment are reflected in other expense in the consolidated statement of operations in the period of disposal.
	Depreciation is computed using the straight-line method over the following useful lives:
		Years
	Office/computer equipment	5-Mar
	Furniture and fixtures	7-May
	Software	3
	Leasehold improvements, which are included in property and equipment, are recorded at cost less accumulated depreciation. Depreciation on leasehold improvements is computed using the straight-line method over the shorter of their estimated useful lives or the lease term, whichever is shorter.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of Long-Lived Assets
	The Company reviews long-lived assets, including intangible assets other than goodwill, for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. In connection with this review, the Company also re-evaluates the periods of depreciation and amortization for these assets. The Company assesses recoverability by determining whether the net book value of the related asset will be recovered through the projected undiscounted future cash flows of the asset. If the Company determines that the carrying value of the asset may not be recoverable, it measures any impairment based on the projected future discounted cash flows as compared to the asset’s carrying value. Through December 31, 2013, the Company has not recorded any impairment charges on its long-lived assets.
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses the Black-Scholes option valuation model to value the derivative instruments at inception and on subsequent valuation dates. The warrants issued with the Company’s series B preferred stock, and to the placement agent in the series B financing, do not have fixed settlement provisions because their exercise prices may be lowered if the Company issues securities at lower prices in the future. The Company was required to include the reset provisions in order to protect the warrant holders from the potential dilution associated with future financings. Accordingly, the warrants are recognized as a derivative instrument. The Company determined the warrants include an implied downside protection feature and performed a Monte-Carlo simulation and concluded that the value of the feature is de minimus and the use of the Black-Scholes valuation model is considered to be a reasonable method to value the warrants. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date (Note 5).
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when an agreement exists, services are performed, prices are fixed or determinable, and collectability is reasonably assured. Revenues are reduced for estimated discounts and other allowances, if any.
	The Company provides advanced medical image analysis on a per analysis basis, and recognizes revenue when the image analysis is completed. Revenue related to project, data, and site management services is recognized as the services are rendered and in accordance with the terms of the contract. Consulting revenue is recognized once the services are rendered and typically charged as an hourly rate.
	Occasionally, the Company provides software development services to its customers, which may require significant development, modification, and customization. Software development revenue is billed on a fixed price basis and recognized upon delivery of the software and acceptance by the customer on a completed contract basis. The Company does not sell software in its ordinary course of business, software licenses, upgrades or enhancements, or post-contract customer services.
	Reimbursements received and related costs incurred for out-of-pocket expenses are separately reported as reimbursement revenues and cost of reimbursement revenues, respectively, in the consolidated financial statements.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development expense relates to the development of new applications and processes, including improvements to existing applications. These costs are expensed as incurred.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	Fair value of financial instruments is defined as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Financial assets and liabilities with readily available, actively quoted prices or for which fair value can be measured from actively quoted prices in active markets generally have more pricing observability and require less judgment in measuring fair value. Conversely, financial assets and liabilities that are rarely traded or not quoted have less price observability and are generally measured at fair value using valuation models that require more judgment. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency of the asset, liability or market and the nature of the asset or liability. The Company has categorized its financial assets and liabilities measured at fair value into a three-level hierarchy. See Note 5 – Derivative Liabilities for a further discussion regarding the Company’s measurement of financial assets and liabilities at fair value.
Preferred Stock, Policy [Policy Text Block]	'
	Preferred Stock
	The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders’ equity.
Convertible Instruments, Policy [Policy Text Block]	'
	Convertible Instruments
	The Company applies the accounting standards for derivatives and hedging and for distinguishing liabilities from equity when accounting for hybrid contracts that feature conversion options. The accounting standards require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (i) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (ii) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (iii) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in results of operations.
	Conversion options that contain variable settlement features such as provisions to adjust the conversion price upon subsequent issuances of equity or equity linked securities at exercise prices more favorable than that featured in the hybrid contract generally result in their bifurcation from the host instrument.
	The Company accounts for convertible debt instruments when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments in accordance with Accounting Standards Codification (“ASC”) 470-20 “Debt with Conversion and Other Options”. The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. The Company also records, when necessary, deemed dividends for the intrinsic value of the conversion options embedded in preferred stock based upon the difference between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred stock.
Common Stock Purchase Warrants and Other Derivative Financial Instruments, Policy [Policy Text Block]	'
	Common Stock Purchase Warrants and Other Derivative Financial Instruments
	The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) provides a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) providing that such contracts are indexed to the Company's own stock as defined in ASC 815-40 "Contracts in Entity's Own Equity" (“ASC 815-40”). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement).  The Company assesses classification of common stock purchase warrants and other free standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued and Adopted Accounting Pronouncements
	The Financial Accounting Standards Board, the Emerging Issues Task Force and the SEC have issued certain accounting standards, updates and regulations as of December 31, 2013 that will become effective in subsequent periods; however, management of the Company does not believe that any of those standards, updates or regulations would have significantly affected the Company’s financial accounting measures or disclosures had they been in effect during 2013 or 2012, and it does not believe that any of them will have a significant impact on the Company’s consolidated financial statements at the time they become effective.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	The Company accounts for share-based awards exchanged for employee services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. These options generally vest over a three or four year period.
	The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, and expected dividend yield. The risk free interest rate is based on U.S. Treasury zero-coupon yield curve over the expected term of the option. The expected term assumption is determined using the weighted average midpoint between vest and expiration for all individuals within the grant. Through the second quarter of 2012, the Company had estimated its expected volatility from an index of historical stock prices of comparable entities whose share prices were publicly traded and averaged with the Company’s historical stock prices, excluding its first ten months of activity due to the discreet and non-recurring nature of the trading. Beginning in the third quarter of 2012, the Company began estimating its expected volatility using only its own historical stock prices, continuing to exclude the first ten months due to the discreet and non-recurring nature of the trading, as management determined this assumption to be a better indicator of value at this time. The Company’s model includes a zero dividend yield assumption, as the Company has not historically paid nor does it anticipate paying dividends on its common stock. The Company’s model does not include a discount for post-vesting restrictions, as the Company has not issued awards with such restrictions. The periodic expense is then determined based on the valuation of the options, and at that time an estimated forfeiture rate is used to reduce the expense recorded. The Company’s estimate of pre-vesting forfeitures is primarily based on the Company’s historical experience and is adjusted to reflect actual forfeitures as the options vest. The estimated forfeiture rates used during the years ended December 31, 2013 and 2012 ranged from 7.1% to 7.3%.
	The following assumptions were used to estimate the fair value of options granted for the years ended December 31, 2013 and 2012 using the Black-Scholes option-pricing model:
		December 31,
		2013			2012
	Risk free interest rate		1.97	%		1.13	%
	Expected term (in years)		6.7			6.32
	Expected volatility		68.22	%		57.98	%
	Expected dividend yield		-			-
Earnings Per Share, Policy [Policy Text Block]	'
	Loss Per Share
	Basic loss per share are computed by dividing the net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares consist of the incremental common shares issuable upon the exercise of stock options (using the treasury stock method) and the conversion of the Company’s convertible preferred stock and warrants (using the if-converted method). Diluted loss per share excludes the shares issuable upon the conversion of preferred stock, the exercise of stock options and warrants from the calculation of net loss per share as their effect would be antidilutive.
	Securities that could potentially dilute earnings per share in the future that were not included in the computation of diluted loss per share consist of the following numbers of shares into which preferred stock could have been converted and shares for which outstanding options and warrants could have been exercised during the years ending December 31, 2013 and 2012:
		2013		2012
	Convertible preferred stock	480,777		480,777
	Warrants to purchase common stock	233,753		238,302
	Non-vested restricted stock awards	984		-
	Options to purchase common stock	425,995		598,044
	Total	1,141,509		1,317,123

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Property Plant And Equipment Useful Life [Table Text Block]	'
	Depreciation is computed using the straight-line method over the following useful lives:
		Years
	Office/computer equipment	5-Mar
	Furniture and fixtures	7-May
	Software	3
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following assumptions were used to estimate the fair value of options granted for the years ended December 31, 2013 and 2012 using the Black-Scholes option-pricing model:
		December 31,
		2013			2012
	Risk free interest rate		1.97	%		1.13	%
	Expected term (in years)		6.7			6.32
	Expected volatility		68.22	%		57.98	%
	Expected dividend yield		-			-
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		2013		2012
	Convertible preferred stock	480,777		480,777
	Warrants to purchase common stock	233,753		238,302
	Non-vested restricted stock awards	984		-
	Options to purchase common stock	425,995		598,044
	Total	1,141,509		1,317,123

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following as of December 31:
		2013		2012
	Office/computer equipment	$	876,393	$	917,638
	Furniture and fixtures		267,939		267,939
	Software		468,226		446,611
	Leasehold improvements		114,669		143,109
			1,727,227		1,775,297
	Less: accumulated depreciation		-1,505,527		-1,375,728
		$	221,700	$	399,569

Patents_Tables

Patents (Tables)	12 Months Ended
	Dec. 31, 2013
Patents [Abstract]	'
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	The weighted-average remaining amortization period is approximately 13 years as of December 31, 2013. The estimated future amortization of the patents is as follows:
	For the Years Ending
	December 31,	Amount
	2014	$	137,574
	2015		137,574
	2016		137,574
	2017		137,574
	2018		137,574
	Thereafter		646,550
	Total	$	1,334,420

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments, Valuation Assumptions [Table Text Block]	'
	The derivative liabilities were valued using the Black-Scholes option valuation model and the following assumptions on the following dates:
		April 3, 2012				December 31, 2012				December 31, 2013
	Series B warrants:
	Risk-free interest rate		0.45	%			0.22	%			0.13	%
	Expected volatility		49.6	%			65.94	%			56.31	%
	Expected life (in years)		2.43				1.69				0.69
	Expected dividend yield		-				-				-
	Number of warrants		90,204				21,423				21,423
	Fair value	$	521,139			$	15,950			$	73
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following table provides the liabilities carried at fair value measured on a recurring basis as of December 31, 2013 and 2012:
					Fair Value Measurements at December 31, 2013
		Total			Quoted			Significant			Significant
		Carrying			prices in			other			unobservable
		Value at			active			observable			inputs
		December 31,			markets			inputs			(Level 3)
		2013			(Level 1)			(Level 2)
	Derivative liabilities	$	73		$	-		$	-		$	73
					Fair Value Measurements at December 31, 2012
		Total			Quoted			Significant			Significant
		Carrying			prices in			other			unobservable
		Value at			active			observable			inputs
		December 31,			markets			inputs			(Level 3)
		2012			(Level 1)			(Level 2)
	Derivative liabilities	$	15,950		$	-		$	-		$	15,950
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table sets forth a summary of the changes in the fair value of our Level 3 financial liabilities that are measured at fair value on a recurring basis:
		Years Ended December 31,
		2013			2012
	Beginning balance	$	15,950		$	156,596
	Net unrealized (gain) loss on derivative financial instruments		-15,877			264,587
	Reclassification to stockholders’ equity					-405,233
	Ending balance	$	73		$	15,950

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the employee stock option activity for the years ended December 31, 2013 and 2012 are as follows:
		Number of			Weighted		Weighted-			Aggregate
		Shares			Average		Average			Intrinsic
					Exercise		Remaining			Value
					Price		Contractual
							Term
	Options outstanding at January 1, 2012		576,869		$	13.25		6.32		$	55,000
	Granted		40,580			11.3
	Exercised		-2,000			-10.1
	Forfeited		-10,282			-14.98
	Expired		-7,663			-19
	Options outstanding at December 31, 2012		597,504			13.03		5.62		$	6,750
	Granted		6,850			5.65
	Exercised		-
	Forfeited		-143,568			-12.35
	Expired		-34,911			-18.11
	Options outstanding at December 31, 2013		425,875			12.72		4.34		$	-
	Options exercisable at December 31, 2013		372,989			12.76		4.74		$	-
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Additional information with respect to the outstanding employee stock options as of December 31, 2013 is as follows:
		Options Outstanding					Options Exercisable
	Exercise Prices	Number		Weighted		Weighted	Number		Weighted
		Outstanding at		Average		Average	Exercisable		Average
		December 31,		Remaining		Exercise	at		Exercise
		2013		Life		Price	December		Price
				(Years)			31, 2013
	$ 4.80 – 9.20	69,663		5.67		7.95	59,926		8.19
	$ 9.21 – 10.15	126,100		4.63		9.83	126,000		9.83
	$ 10.16 – 12.05	108,745		4.21		11.56	94,952		11.61
	$ 12.06 – 21.75	70,459		7.01		15.07	41,203		15.07
	$ 21.76 – 41.50	50,908		1.95		25.65	50,908		25.65
		425,875		4.77		12.72	372,989		12.76
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	For the years ended December 31, 2013 and 2012, the Company’s consolidated statements of operations reflect $257,263 and $612,946, respectively, of stock-based compensation expense for stock options granted under its long-term incentive plans, which is allocated as follows:
		For Years Ended December 31,
		2013			2012
	Cost of service revenues	$	50,466		$	57,984
	Research and development		64,917			78,456
	Sales and marketing		11,101			10,222
	General and administrative		130,779			466,284
	Total stock-based compensation	$	257,263		$	612,946
Schedule Of Share Based Compensation Non Vested Stock Options Activity [Table Text Block]	'
	A summary of the status of the non-vested shares as of December 31, 2013 and changes during the years ended December 31, 2013 and 2012, is presented below:
	Non-vested Shares	Shares		Weighted-
				Average
				Grant-Date
				Fair Value
				Per Share
	Non-vested at January 1, 2012	234,647		$	12.47
	Granted	40,580			11.3
	Vested.	-94,484			-11.38
	Cancelled Grants	-7,807			-14.72
	Non-vested at December 31, 2012	172,936		$	12.69
	Granted	6,850			5.65
	Vested	-78,722			-11.88
	Cancelled Grants	-48,178			-13.26
	Non-vested at December 31, 2013	52,886		$	12.46
Schedule Of Stock Options Outstanding [Table Text Block]	'
	The total amount of stock options outstanding as of December 31, 2013 is:
	Stock options granted to employees	425,875
	Stock options granted to consultants	120
	Total outstanding	425,995
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	A summary of the restricted stock award activity for the year ended December 31, 2013 is as follows:
		Number		Weighted
		of Units		Average
				Grant
				Date Fair
				Value
	Non-vested at January 1, 2013	-
	Granted	15,927		7.4
	Vested	-11,992		-7.4
	Cancelled/Forfeited	-2,951		-7.4
	Non-vested at December 31, 2013	984		7.4

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
	The income tax provision (benefit) consists of the following:
		2013		2012
	Current
	Federal	$	-	$	-
	State		-		-
			-		-
	Deferred
	Federal		-846,095		-309,448
	State		-99,926		-42,649
	Change in valuation allowance		946,021		352,097
			-		-
	Total income tax provision	$	-	$	-
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The total net deferred tax asset and liabilities as of December 31, 2013 and 2012 consists of the following:
		2013		2012
	Net operating loss carryforwards	$	4,095,519	$	3,112,584
	Intangible assets		658,055		788,990
	Accrued expenses		146,249		117,010
	Credit carryforwards		287,756		166,693
	Stock-based compensation		958,607		1,095,050
	Total deferred tax asset		6,146,186		5,280,327
	Deferred tax liability:
	Property and equipment		-11,526		-91,688
	Subtotal		6,134,660		5,188,639
	Less: valuation allowance		6,134,660		5,188,639
	Total net deferred tax asset	$	-	$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The difference between the U.S. federal statutory and effective income tax rates for the years ended December 31, 2013 and 2012 is as follows:
		2013		2012
	U.S. federal statutory tax rate	-34	%	-34	%
	State and local income taxes, net of federal benefit	-3.64		-2.67
	Stock-based compensation	7.56		8.27
	(Gain) loss from derivative financial instrument	-0.2		5.88
	Research and development credit	-4.41		-0.97
	Other	-0.17		0.46
		-34.86		-23.03
	Less: valuation allowance	34.86		23.03
	Provision for income taxes	-	%	-	%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum rental commitments under non-cancelable operating leases are as follows:
	For the Years Ending
	December 31,	Amount
	2014		318,409
	2015		324,777
	2016		331,273
	2017		167,276
	Total	$	1,141,735

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation (Details Textual) (USD $)	1 Months Ended
	Aug. 31, 2013	Sep. 05, 2013
Stockholders Equity, Reverse Stock Split	'1-for-10	'
Current Market Price	'	$4.84
Closing Bid Price	'	$1

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2013
Software [Member]	'
Property, Plant and Equipment, Useful Life	'3 years
Maximum [Member] | Office/computer equipment [Member]	'
Property, Plant and Equipment, Useful Life	'5 years
Minimum [Member] | Office/computer equipment [Member]	'
Property, Plant and Equipment, Useful Life	'3 years
Minimum [Member] | Furniture and Fixtures [Member]	'
Property, Plant and Equipment, Useful Life	'5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Risk free interest rate	1.97%	1.13%
Expected term (in years)	'6 years 8 months 12 days	'6 years 3 months 25 days
Expected volatility	68.22%	57.98%
Expected dividend yield	0.00%	0.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,141,509	1,317,123
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	480,777	480,777
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	233,753	238,302
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	984	0
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	425,995	598,044

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Description Of Classification Of Derivative Instruments	'Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date (Note 5).	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Average Forfeiture Rate	7.10%	7.30%
Patents [Member]	'	'
Finite-Lived Intangible Asset, Useful Life	'20 years	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment, Gross, Total	$1,727,227	$1,775,297
Less: accumulated depreciation	-1,505,527	-1,375,728
Property, Plant and Equipment, Net, Total	221,700	399,569
Software [Member]	'	'
Property, Plant and Equipment, Gross, Total	468,226	446,611
Office/computer equipment [Member]	'	'
Property, Plant and Equipment, Gross, Total	876,393	917,638
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment, Gross, Total	267,939	267,939
Leasehold improvements [Member]	'	'
Property, Plant and Equipment, Gross, Total	$114,669	$143,109

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Depreciation	$229,724	$285,074
Property Plant And Equipment, Cost Of Dispositions	126,277	86,297
Impairment of Long-Lived Assets Held-for-use	99,925	86,297
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	2,089	0
Proceeds from Sale of Property, Plant, and Equipment, Total	$28,441	'

Patents_Details

Patents (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
2014	$137,574	'
2015	137,574	'
2016	137,574	'
2017	137,574	'
2018	137,574	'
Thereafter	646,550	'
Total	$1,334,420	$1,470,436

Patents_Details_Textual

Patents (Details Textual) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	24-May-02	31-May-02	Dec. 31, 2013	Dec. 31, 2012	24-May-02
				Patents [Member]	Patents [Member]	Patents [Member]	University Of Rochester [Member]
Acquisition Of Patents	$17,548	$23,157	'	$1,500,000	'	'	'
Number of warrants	'	'	'	'	'	'	357,075
Fair Value Of Warrants	'	'	157,000	'	'	'	'
Additional Investment	'	'	'	'	1,075,990	'	'
Finite-Lived Intangible Assets, Accumulated Amortization	'	'	'	'	1,379,213	1,242,410	'
Amortization of Intangible Assets	136,803	135,659	'	'	'	'	'
Finite-Lived Intangible Assets, Remaining Amortization Period	'13 years	'	'	'	'	'	'
Patents written Off	$16,761	'	'	'	'	'	'

Derivative_Liabilities_Details

Derivative Liabilities (Details) (USD $)	1 Months Ended	12 Months Ended
	Apr. 30, 2012	Dec. 31, 2013	Dec. 31, 2012
Series B warrants:	'	'	'
Fair value	'	$73	$15,950
Series B Warrant [Member]	'	'	'
Series B warrants:	'	'	'
Risk-free interest rate	0.45%	0.13%	0.22%
Expected volatility	49.60%	56.31%	65.94%
Expected life (in years)	'2 years 5 months 5 days	'8 months 8 days	'1 year 8 months 8 days
Expected dividend yield	0.00%	0.00%	0.00%
Number of warrants	90,204	21,423	21,423
Fair value	$521,139	$73	$15,950

Derivative_Liabilities_Details1

Derivative Liabilities (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Derivative liabilities	$73	$15,950	'
Fair Value, Inputs, Level 1 [Member]	'	'	'
Derivative liabilities	0	0	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Derivative liabilities	0	0	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Derivative liabilities	$73	$15,950	$156,596

Derivative_Liabilities_Details2

Derivative Liabilities (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Beginning balance	$15,950	'
Net unrealized (gain) loss on derivative financial instruments	15,877	-264,587
Ending balance	73	15,950
Fair Value, Inputs, Level 3 [Member]	'	'
Beginning balance	15,950	156,596
Net unrealized (gain) loss on derivative financial instruments	-15,877	264,587
Reclassification to stockholdersb equity	'	-405,233
Ending balance	$73	$15,950

Derivative_Liabilities_Details3

Derivative Liabilities (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Change In Fair Value Of Derivative Liability	$15,877	$140,646
Gain (Loss) On Derivative Instruments, Net, Pretax	15,877	-264,587
Reclassification Of Derivative Liabilities To Additional Paid In Capital In Connection With Series C1 Preferred Stock Issuance	$0	$405,233
Series B Warrant [Member]	'	'
Class of Warrant or Right, Outstanding	21,423	'
Antidilutive Adjustments Provisions Eliminated Warrants	76,198	'

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Apr. 30, 2012	Dec. 31, 2013	Dec. 31, 2012
Convertible preferred stock, shares authorized	'	15,000,000	15,000,000
Preferred Stock, Par or Stated Value Per Share	'	$0.00	$0.00
Common Stock, Shares Authorized	'	85,000,000	85,000,000
Common Stock, Par Or Stated Value Per Share	'	$0.00	$0.00
Preferred Stock and Warrant Purchase Agreement Shares To Be Issued Upon Conversion Of Preferred Stock	249,107	'	'
Preferred Stock Deemed Dividends	'	$0	$1,806,919
Cash Dividends On Series B Preferred Stock	'	0	12,000
Series B Warrant [Member]	'	'	'
Class of Warrant or Right, Outstanding	'	21,423	'
Common Stock [Member]	'	'	'
Share Price	'	'	$15.60
Former Chief Executive Officer [Member]	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance	'	35,000	'
Long Term Incentive Plan 2001 and 2005 [Member]	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance	'	232,794	'
Long Term Incentive Plan 2006 [Member]	'	'	'
Common Stock, Capital Shares Reserved for Future Issuance	'	690,000	'
Series A Convertible Preferred Stock [Member]	'	'	'
Preferred Stock Designated During Period Shares	'	8,400	'
Stock Conversion Ratio	'	83.036	'
Series B Preferred Stock [Member]	'	'	'
Preferred Stock Designated During Period Shares	'	6,000	'
Preferred Stock, Dividend Rate, Percentage	'	8.00%	8.00%
Series C1 Convertible Preferred Stock [Member]	'	'	'
Convertible preferred stock, shares authorized	'	3,000	'
Proceeds from Issuance or Sale of Equity	'	'	3,000,000
Payments of Stock Issuance Costs	'	'	334,000
Preferred Stock and Warrant Purchase Agreement Shares To Be Issued Upon Conversion Of Preferred Stock	'	'	249,107
Interest and Dividends Payable, Total	'	209,333	'
Preferred Stock, Dividend Rate, Percentage	'	4.00%	'
Series C-2 Preferred Stock [Member]	'	'	'
Future Proceeds From Issuance Or Sale Of Equity	'	3,000,000	'
Preferred Stock Designated During Period Shares	'	3,000	'
Series C Preferred Stock [Member]	'	'	'
Convertible preferred stock, shares authorized	'	'	6,000
Preferred Stock and Warrant Purchase Agreement Warrants Authorized For Issuance To Acquire Common Stock Shares Number	272,263	'	'
Preferred Stock and Warrant Purchase Agreement Exercise Price Of Warrants Authorized	12.043	'	'
Purchase Price Of Warrants and Preferred Stock	6,000,000	'	'
Preferred Stock, Liquidation Preference Per Share	1,000	'	'
Preferred Stock Conversion Price Per Share	12.043	'	'
Preferred Stock, Dividend Rate, Percentage	'	4.00%	4.00%
Series C-1 Warrants [Member]	'	'	'
Preferred Stock and Warrant Purchase Agreement, Warrants Issued To Acquire Common Stock Shares, Number	'	136,132	136,132
Convertible Preferred Stock Series C - 2 [Member]	'	'	'
Convertible preferred stock, shares authorized	'	3,000	3,000
Preferred Stock, Liquidation Preference Per Share	'	$1,000	$1,000
Series B Convertible Preferred Stock [Member]	'	'	'
Preferred Stock, Liquidation Preference Per Share	'	$1,000	'
Interest and Dividends Payable, Total	'	$84,000	'
Stock Conversion Ratio	'	83.036	'
Annual Dividend Rate	'	8.00%	'

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Options outstanding - Number of Shares (in shares)	597,504	576,869	'
Granted - Number of Shares (in shares)	6,850	40,580	'
Exercised - Number of Shares (in shares)	0	-2,000	'
Forfeited - Number of Shares (in shares)	143,568	10,282	'
Expired - Number of Shares (in shares)	-34,911	-7,663	'
Options outstanding - Number of Shares (in shares)	425,875	597,504	576,869
Option Exercisable-Number of Shares	372,989	'	'
Granted - Weighted Average Exercise Price (in dollars per share)	$5.65	$11.30	'
Exercised - Weighted Average Exercise Price (in dollars per share)	'	($10.10)	'
Forfeited - Weighted Average Exercise Price (in dollars per share)	($12.35)	($14.98)	'
Expired - Weighted Average Exercise Price (in dollars per share)	($18.11)	($19)	'
Exercisable, Weighted Average Exercise Price	$12.76	'	'
Options outstanding at September 30, 2013 - Weighted Average Remaining Contractual Term (in years)	'4 years 9 months 7 days	'5 years 7 months 13 days	'6 years 3 months 25 days
Options exercisable - Weighted Average Remaining Contractual Term (in years)	'4 years 8 months 26 days	'	'
Aggregate Outstanding, Intrinsic Value	$0	$6,750	$55,000
Aggregate Exercisable, Intrinsic Value	$0	'	'
Beginning balance, Options outstanding - Exercise price (in dollars per share)	$13.03	$13.25	'
Ending balance, Options outstanding - Exercise price (in dollars per share)	$12.72	$13.03	$13.25

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Option, Number Outstanding	425,875	597,504	576,869
Stock Option, Weighted Average Remaining Life (Years)	'4 years 9 months 7 days	'5 years 7 months 13 days	'6 years 3 months 25 days
Stock Option, Weighted Average Exercise Price	$12.72	$13.03	$13.25
Options Exercisable, Number Exercisable	372,989	'	'
Options Exercisable, Weighted Average Exercise Price	$12.76	'	'
Option One [Member]	'	'	'
Stock Option, Number Outstanding	69,663	'	'
Stock Option, Weighted Average Remaining Life (Years)	'5 years 8 months 1 day	'	'
Stock Option, Weighted Average Exercise Price	$7.95	'	'
Options Exercisable, Number Exercisable	59,926	'	'
Options Exercisable, Weighted Average Exercise Price	$8.19	'	'
Option One [Member] | Minimum [Member]	'	'	'
Stock Option, Exercise Prices	$4.80	'	'
Option One [Member] | Maximum [Member]	'	'	'
Stock Option, Exercise Prices	$9.20	'	'
Option Two [Member]	'	'	'
Stock Option, Number Outstanding	126,100	'	'
Stock Option, Weighted Average Remaining Life (Years)	'4 years 7 months 17 days	'	'
Stock Option, Weighted Average Exercise Price	$9.83	'	'
Options Exercisable, Number Exercisable	126,000	'	'
Options Exercisable, Weighted Average Exercise Price	$9.83	'	'
Option Two [Member] | Minimum [Member]	'	'	'
Stock Option, Exercise Prices	$9.21	'	'
Option Two [Member] | Maximum [Member]	'	'	'
Stock Option, Exercise Prices	$10.15	'	'
Option Three [Member]	'	'	'
Stock Option, Number Outstanding	108,745	'	'
Stock Option, Weighted Average Remaining Life (Years)	'4 years 2 months 16 days	'	'
Stock Option, Weighted Average Exercise Price	$11.56	'	'
Options Exercisable, Number Exercisable	94,952	'	'
Options Exercisable, Weighted Average Exercise Price	$11.61	'	'
Option Three [Member] | Minimum [Member]	'	'	'
Stock Option, Exercise Prices	$10.16	'	'
Option Three [Member] | Maximum [Member]	'	'	'
Stock Option, Exercise Prices	$12.05	'	'
Option Four [Member]	'	'	'
Stock Option, Number Outstanding	70,459	'	'
Stock Option, Weighted Average Remaining Life (Years)	'7 years 4 days	'	'
Stock Option, Weighted Average Exercise Price	$15.07	'	'
Options Exercisable, Number Exercisable	41,203	'	'
Options Exercisable, Weighted Average Exercise Price	$15.07	'	'
Option Four [Member] | Minimum [Member]	'	'	'
Stock Option, Exercise Prices	$12.06	'	'
Option Four [Member] | Maximum [Member]	'	'	'
Stock Option, Exercise Prices	$21.75	'	'
Option Five [Member]	'	'	'
Stock Option, Number Outstanding	50,908	'	'
Stock Option, Weighted Average Remaining Life (Years)	'1 year 11 months 12 days	'	'
Stock Option, Weighted Average Exercise Price	$25.65	'	'
Options Exercisable, Number Exercisable	50,908	'	'
Options Exercisable, Weighted Average Exercise Price	$25.65	'	'
Option Five [Member] | Minimum [Member]	'	'	'
Stock Option, Exercise Prices	$21.76	'	'
Option Five [Member] | Maximum [Member]	'	'	'
Stock Option, Exercise Prices	$41.50	'	'

ShareBased_Compensation_Detail2

Share-Based Compensation (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Long-Term Incentive Plans [Member]	'	'
Stock-based compensation	$257,263	$612,946
Cost of Sales [Member]	'	'
Stock-based compensation	50,466	57,984
Research and Development Expense [Member]	'	'
Stock-based compensation	64,917	78,456
Selling and Marketing Expense [Member]	'	'
Stock-based compensation	11,101	10,222
General and Administrative Expense [Member]	'	'
Stock-based compensation	$130,779	$466,284

ShareBased_Compensation_Detail3

Share-Based Compensation (Details 3) (Non-Vested [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Non-Vested [Member]	'	'
Non-vested, Shares	172,936	234,647
Granted	6,850	40,580
Vested, Number of Units	-78,722	-94,484
Cancelled Grants	-48,178	-7,807
Non-vested, Shares	52,886	172,936
Non-vested, Weighted-Average Grant-Date Fair Value Per Share	$12.69	$12.47
Granted, Weighted-Average Grant-Date Fair Value Per Share	$5.65	$11.30
Vested, Weighted-Average Grant-Date Fair Value Per Share	($11.88)	($11.38)
Cancelled Grants, Weighted-Average Grant-Date Fair Value Per Share	($13.26)	($14.72)
Non-vested, Weighted-Average Grant-Date Fair Value Per Share	$12.46	$12.69

ShareBased_Compensation_Detail4

Share-Based Compensation (Details 4)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number	425,875	597,504	576,869
Employee Stock Option [Member]	'	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number	425,995	'	'
Employees [Member]	'	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number	425,875	'	'
Consultants [Member]	'	'	'
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number	120	'	'

ShareBased_Compensation_Detail5

Share-Based Compensation (Details 5) (Restricted Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Restricted Stock [Member]	'
Non-vested, Shares	0
Granted	15,927
Vested	-11,992
Cancelled/Forfeited	-2,951
Non-vested, Shares	984
Non-vested, Weighted-Average Grant-Date Fair Value Per Share	'
Granted, Weighted-Average Grant-Date Fair Value Per Share	$7.40
Vested, Weighted-Average Grant-Date Fair Value Per Share	($7.40)
Cancelled Grants, Weighted-Average Grant-Date Fair Value Per Share	($7.40)
Non-vested, Weighted-Average Grant-Date Fair Value Per Share	$7.40

ShareBased_Compensation_Detail6

Share-Based Compensation (Details Textual) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Aug. 31, 2013

Oct. 25, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

CEO And CFO [Member]

Chief Financial Officer [Member]

Former Chief Executive Officer [Member]

Maximum [Member]

Minimum [Member]

Long Term Incentive Plan 2006 [Member]

Long Term Incentive Plan 2006 [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Executive Officers [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Long-Term Incentive Plans [Member]

Long-Term Incentive Plans [Member]

Common Stock [Member]

Non-Employee Stock Options [Member]

Share Based Compensation Options Grants In Period Weighted Average Grant Date Fair Value

$25,081

$250,571

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

'

251,155

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total

6,850

40,580

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

'

Stock Issued During Period, Value, Stock Options Exercised

'

20,200

'

'

'

'

'

'

'

'

'

'

'

'

20,200

'

'

2

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

0

2,000

'

'

2,000

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total

205,194

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'1 year 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

569,988

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price

'

'

'

'

'

'

$6.85

$1.12

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

34,911

7,663

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

421

Stock Issued During Period, Shares, Issued for Services

'

'

'

15,927

'

'

'

'

0

51,761

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Issued for Services

'

'

'

117,861

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation

$352,727

$612,946

'

'

'

'

'

'

'

'

$95,464

$0

'

'

'

$257,263

$612,946

'

'

Share Price

'

'

'

$7.40

'

'

'

'

'

'

'

'

'

'

'

'

'

$15.60

'

Stock Issued During Period, Shares, Restricted Stock Award, Forfeited

'

'

'

'

2,951

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

'

'

'

'

'

'

'

$68,549

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance

425,875

597,504

576,869

'

'

'

'

'

'

'

'

'

'

425,995

'

'

'

'

'

Stock Issued During Period, Shares, Share-based Compensation, Forfeited

'

'

'

124,731

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross

'

'

'

'

'

11,992

'

'

'

'

'

'

'

'

'

'

'

'

'

Benefit_Plan_Details_Textual

Benefit Plan (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2009
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees Gross Pay	'	'	50.00%
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	'	'	3.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$0	$145,479	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current	$0	$0
State	0	0
Current Income Tax Expense (Benefit), Total	0	0
Federal	-846,095	-309,448
State	-99,926	-42,649
Change in valuation allowance	946,021	352,097
Deferred Income Tax Expense (Benefit), Total	0	0
Total income tax provision	$0	$0

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Net operating loss carryforwards	$4,095,519	$3,112,584
Intangible assets	658,055	788,990
Accrued expenses	146,249	117,010
Credit carryforwards	287,756	166,693
Stock-based compensation	958,607	1,095,050
Total deferred tax asset	6,146,186	5,280,327
Property and equipment	-11,526	-91,688
Subtotal	6,134,660	5,188,639
Less: valuation allowance	6,134,660	5,188,639
Total net deferred tax asset	$0	$0

Income_Taxes_Details_2

Income Taxes (Details 2)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
U.S. federal statutory tax rate	-34.00%	-34.00%
State and local income taxes, net of federal benefit	-3.64%	-2.67%
Stock-based compensation	7.56%	8.27%
(Gain) loss from derivative financial instrument	-0.20%	5.88%
Research and development credit	-4.41%	-0.97%
Other	-0.17%	0.46%
Effective Income Tax Rate Reconciliation, Percent, Total	-34.86%	-23.03%
Less: valuation allowance	34.86%	23.03%
Provision for income taxes	0.00%	0.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Dec. 31, 2013
Valuation Allowance Percentage	100.00%
Operating Loss Carryforwards	$11,264,000
Additional Paid-in Capital [Member]	'
Operating Loss Carryforwards	$677,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2013
2014	$318,409
2015	324,777
2016	331,273
2017	167,276
Total	$1,141,735

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	1 Months Ended			12 Months Ended		1 Months Ended	12 Months Ended
	Jun. 30, 2012	Apr. 30, 2010	Jul. 31, 2007	Dec. 31, 2013	Dec. 31, 2012	Oct. 25, 2013	Dec. 31, 2013	Oct. 25, 2013	31-May-14
						Services Agreements [Member]	Seperation Agreement [Member]	Seperation Agreement [Member]	Subsequent Event [Member]
									Seperation Agreement [Member]
Leasing Space Square Feet	'19,500	'	'19,500	'	'	'	'	'	'
Base Annual Rent	$309,075	'	'	$5,222	'	'	'	'	'
Operating Leases, Rent Expense	'	'	'	322,993	326,215	'	'	'	'
Lease Term	'5 Years	'36	'	'	'	'	'	'	'
Rent Increased Percentage	2.00%	'	'	'	'	'	'	'	'
Base Annual Rent Recognized	'	'	'	1,306	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	'	'	'	'	'	'	11,992	'	'
Seperation Payment	'	'	'	'	'	'	'	25,310	'
Benefits From Seperation Agreement	'	'	'	'	'	'	'	'	8,213
Bonus Earned	'	'	'	'	'	'	98,136	'	'
Employee Receivables	'	'	'	'	'	'	20,867	'	'
Severance Costs Payable	'	'	'	'	'	'	133,897	'	'
Consulting Fee Monthly Rate	'	'	'	'	'	$25,310	'	'	'

Related_Parties_Details_Textua

Related Parties (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Apr. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
		Merck Global Health Innovation Fund Llc [Member]	Merck Global Health Innovation Fund Llc [Member]	Series C-1 Preferred Stock [Member]	Series C-1 Warrants [Member]	Series C-1 Warrants [Member]
Preferred Stock and Warrant Purchase Agreement Shares Issued	'	'	'	3,000	'	'
Preferred Stock and Warrant Purchase Agreement, Warrants Issued To Acquire Common Stock Shares, Number	'	'	'	'	136,132	136,132
Revenue from Related Parties	'	$368,977	$1,127,330	'	'	'
Accounts Receivable, Related Parties	'	$87,200	$96,096	'	'	'
Common stock issuable upon conversion of preferred stock	249,107	'	'	'	'	'

Concentration_of_Credit_Risk_D

Concentration of Credit Risk (Details Textual)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Customer 1 [Member]	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	34.00%	45.00%
Concentration Risk, Percentage	42.00%	45.00%
Customer 2 [Member]	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	13.00%	10.00%
Concentration Risk, Percentage	12.00%	'
Customer 3 [Member]	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	13.00%	'
Concentration Risk, Percentage	11.00%	'
Customer 4 [Member]	'	'
Entity-Wide Accounts Receivable, Major Customer, Percentage	11.00%	'